Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 13/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914690 | 0.91 | S1PR2 (0.84) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23915579 | 0.91 | S1PR2 (0.82) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23915576 | 0.90 | S1PR2 (0.67) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23908830 | 0.90 | S1PR2 (1.00) | S1PR2KCNH2AKR1B1TSHRCMA1 | |
| SCHEMBL23914607 | 0.90 | S1PR2 (0.77) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23915328 | 0.88 | S1PR2 (0.68) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23914820 | 0.87 | S1PR2 (0.94) | S1PR2KCNH2AKR1B1TSHRCMA1 | |
| SCHEMBL23908800 | 0.82 | S1PR2 (1.00) | S1PR2AKR1B1TSHRCMA1 | |
| SCHEMBL23914693 | 0.81 | S1PR2 (0.82) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23909034 | 0.80 | S1PR2 (0.81) | S1PR2CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885CYP1A2 1079/4885CYP3A4 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.